BACKGROUND: The laminin (LN) gamma2 chain expression has been linked to tumor invasion and prognosis. To provide a convenient clinical use, procedures that analyze LNgamma2 expression by using the serum and/or urine of patients should be developed. METHODS: The serum concentrations of the N-terminal fragments of the LNgamma2 chain in 73 patients with head and neck squamous cell carcinomas were measured by immunoassay. RESULTS: The concentrations of the LNgamma2 fragments ranged between 14.5 and 324.2 ng/mL, and the normal upper limit was estimated to be 50 ng/mL. The LNgamma2 fragment concentrations increased according to the T classification. The amount of elevated LNgamma2 fragment concentrations decreased after the use of curative treatments. Three patients displayed a continuous increase of the concentrations and subsequently died of the diseases. CONCLUSIONS: The serum concentrations of the LNgamma2 fragments may prove useful in assessing the treatment results and clinical courses of patients with head and neck squamous cell carcinomas.
BACKGROUND: The laminin (LN) gamma2 chain expression has been linked to tumor invasion and prognosis. To provide a convenient clinical use, procedures that analyze LNgamma2 expression by using the serum and/or urine of patients should be developed. METHODS: The serum concentrations of the N-terminal fragments of the LNgamma2 chain in 73 patients with head and neck squamous cell carcinomas were measured by immunoassay. RESULTS: The concentrations of the LNgamma2 fragments ranged between 14.5 and 324.2 ng/mL, and the normal upper limit was estimated to be 50 ng/mL. The LNgamma2 fragment concentrations increased according to the T classification. The amount of elevated LNgamma2 fragment concentrations decreased after the use of curative treatments. Three patients displayed a continuous increase of the concentrations and subsequently died of the diseases. CONCLUSIONS: The serum concentrations of the LNgamma2 fragments may prove useful in assessing the treatment results and clinical courses of patients with head and neck squamous cell carcinomas.
Authors: D Korbakis; A Dimitromanolakis; I Prassas; G J Davis; E Barber; K L Reckamp; I Blasutig; E P Diamandis Journal: Br J Cancer Date: 2015-07-16 Impact factor: 7.640
Authors: Adriane S Siqueira; Monique P Pinto; Mário C Cruz; Basilio Smuczek; Karen S P Cruz; José Alexandre M Barbuto; Daisuke Hoshino; Alissa M Weaver; Vanessa M Freitas; Ruy G Jaeger Journal: Oncotarget Date: 2016-07-26
Authors: A Sankiewicz; L Romanowicz; P Laudanski; B Zelazowska-Rutkowska; B Puzan; B Cylwik; E Gorodkiewicz Journal: Anal Bioanal Chem Date: 2016-05-21 Impact factor: 4.142